Scarica l'app Stockscreener
70.65
3.64%
-2.67
Dopo l'orario di chiusura:
70.55
-0.10
-0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$73.32
Aprire:
$72.01
Volume 24 ore:
538.98K
Relative Volume:
0.65
Capitalizzazione di mercato:
$2.41B
Reddito:
$55.63M
Utile/perdita netta:
$-158.10M
Rapporto P/E:
-8.3905
EPS:
-8.4202
Flusso di cassa netto:
$-203.94M
1 W Prestazione:
-7.49%
1M Prestazione:
-5.62%
6M Prestazione:
-1.97%
1 anno Prestazione:
+46.64%
Intervallo 1D:
$70.60
$73.50
Intervallo di 1 settimana:
$70.60
$77.75
Portata 52W:
$33.40
$109.00
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
70.65 | 2.50B | 55.63M | -158.10M | -203.94M | -8.4202 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Iniziato | Wedbush | Neutral |
| 2026-03-17 | Iniziato | TD Cowen | Buy |
| 2026-02-10 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Iniziato | Citigroup | Buy |
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Nektar CEO Opens Door To Finance Questions In Eli Lilly Trial - Law360
Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata - clinicaltrialvanguard.com
Eli Lilly 'Sabotaged' Rezpeg's Development, Nektar Tells Jury - Law360
Lancet Phase 2b REZOLVE-AD Data Could Be A Game Changer For Nektar Therapeutics (NKTR) - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
2026-09-06 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect | NDAQ:NKTR | Press Release - stockhouse.com
Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Peer‑Reviewed REZOLVE‑AD Phase 2b Data Could Be A Game Changer For Nektar Therapeutics (NKTR) - simplywall.st
Is Nektar Therapeutics (NKTR) Undervalued As Lancet Data Supports Its Phase 3 Path? - simplywall.st
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Nektar Therapeutics’ Billion-Dollar Balance Sheet Faces a Multi-Year Test - AlphaStreet
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test - Yahoo Finance
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis - PR Newswire
How Investors Are Reacting To Nektar Therapeutics (NKTR) Q2 Loss, ESOP Shelf Registration And Financing Flexibility - simplywall.st
JPMorgan Chase & Co. Initiates Coverage on Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect - ACCESS Newswire
Nektar Therapeutics chief R&D officer Zalevsky sells $13,388 in shares - Investing.com
Nektar Therapeutics CEO Howard W. Robin sells $30,087 in stock By Investing.com - Investing.com South Africa
Nektar Therapeutics CEO Howard W. Robin sells $30,087 in stock - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 186 Shares of Stock - MarketBeat
Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $30,087.64 in Stock - MarketBeat
Nektar (NKTR) Q2 2026 Earnings Call Transcript - AOL.com
Nektar Therapeutics Stock Historical Valuations | XTER:ITH0 - GuruFocus
Nektar Therapeutics (NKTR) exec sells shares only to cover taxes - Stock Titan
Nektar Therapeutics Stock Operating Data - GuruFocus
NKTR Stock Quote Price and Forecast - CNN
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Nektar Therapeutics (XTER:ITH0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Nektar Therapeutics (XTER:ITH0) Stock News, Headlines & Updates - GuruFocus
Nektar Therapeutics (XTER:ITH0) Stock Price, Trades & News - GuruFocus
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets - Moomoo
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Nektar (NASDAQ: NKTR) exec to sell 186 shares, partly for taxes - Stock Titan
Nektar Therapeutics (NASDAQ: NKTR) insider plans 418-share sale - Stock Titan
NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
2026-08-16 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation | NDAQ:NKTR | Press Release - Stockhouse
Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress - simplywall.st
Piper Sandler Reaffirms Their Buy Rating on Nektar Therapeutics (NKTR) - The Globe and Mail
NKTR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise - Yahoo Finance
Two Seas Capital group (NKTR) reports 9.1% Nektar Therapeutics ownership via investment funds - Stock Titan
Biotechnology Value Fund group (NKTR) discloses 7.1% beneficial stake in Nektar - Stock Titan
Is Nektar Therapeutics (NKTR) Still Below Fair Value After Its Recent Run Up? - Sahm
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming (NKTR) - Seeking Alpha
Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch - Yahoo Finance
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus - TradingView
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):